Current treatment of inflammatory bowel disease in children

被引：11
作者：
Markowitz, J. [1 ]
机构：
[1] Schneider Childrens Hosp, NYU Sch Med, Div Pediat Gastroenterol, N Shore Long Isl Jewish Hlth Syst, New Hyde Pk, NY 11042 USA
来源：
DIGESTIVE AND LIVER DISEASE | 2008年 / 40卷 / 01期
关键词：
5-ASA; biologic therapy; children; corticosteroids; IBD; immunomodulators; nutritional therapy;
D O I：
10.1016/j.dld.2007.07.167
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Children with inflammatory bowel disease present formidable therapeutic challenges. As both Crohn's disease and ulcerative colitis remain medically incurable conditions associated with potentially significant morbidity, the focus of treatment must be to reduce or eliminate symptoms, optimize nutritional status, promote normal growth and development, prevent complications and minimize the potential psychological effects of these chronic illnesses. This review focuses on the evidence supporting the treatments currently used in children with inflammatory bowel disease, and suggests potential treatment algorithms for particular clinical circumstances. (c) 2007 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：16 / 21
页数：6
相关论文
共 34 条
[1]   Methotrexate for induction of remission in refractory Crohn's disease [J].
Alfadhli, AAF ;
McDonald, JWD ;
Feagan, BG .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (01)
[2]   Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab [J].
Barrie, Arthur ;
Plevy, Scott .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2006, 35 (04) :883-+
[3]   Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease [J].
Borrelli, O ;
Bascietto, C ;
Viola, F ;
de Mesquita, MB ;
Barbato, M ;
Mancini, V ;
Bosco, S ;
Cucchiara, S .
DIGESTIVE AND LIVER DISEASE, 2004, 36 (05) :342-347
[4]   Oral tacrolimus treatment of severe colitis in children [J].
Bousvaros, A ;
Kirschner, BS ;
Werlin, SL ;
Parker-Hartigan, L ;
Daum, F ;
Freeman, KB ;
Balint, JP ;
Day, AS ;
Griffiths, AM ;
Zurakowski, D ;
Ferry, GD ;
Leichtner, AM .
JOURNAL OF PEDIATRICS, 2000, 137 (06) :794-799
[5]   Toxicity of infliximab in the course of treatment of Crohn's disease [J].
Bratcher, JM ;
Korelitz, BI .
EXPERT OPINION ON DRUG SAFETY, 2006, 5 (01) :9-16
[6]   Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease [J].
Corken Mackey, Ann ;
Green, Lanh ;
Liang, Li-ching ;
Dinndorf, Patricia ;
Avigan, Mark .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2007, 44 (02) :265-267
[7]   Review article: thiopurines in inflammatory bowel disease [J].
Derijks, L. J. J. ;
Gilissen, L. P. L. ;
Hooymans, P. M. ;
Hommes, D. W. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (05) :715-729
[8]   Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence [J].
Desreumaux, P. ;
Ghosh, S. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 :2-9
[9]   Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease [J].
Dubinsky, MC ;
Lamothe, S ;
Yang, HY ;
Targan, SR ;
Sinnett, D ;
Théorêt, Y ;
Seidman, EG .
GASTROENTEROLOGY, 2000, 118 (04) :705-713
[10]   Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial [J].
Escher, JC .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2004, 16 (01) :47-54
1234